Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1324 Neoplasms 982 Carcinoma, Non-Small-Cell Lung 860 Prostatic Neoplasms 724 Colorectal Neoplasms 666 Lung Neoplasms 551 Leukemia, Myeloid, Acute 475 Neoplasm Metastasis 434 Pancreatic Neoplasms 419 Carcinoma, Hepatocellular 407 Multiple Myeloma 396 Ovarian Neoplasms 392 Stomach Neoplasms 379 Recurrence 364 Squamous Cell Carcinoma of Head and Neck 325 Melanoma 294 Brain Neoplasms 287 Uterine Cervical Neoplasms 283 Triple Negative Breast Neoplasms 271 Glioblastoma 264 Head and Neck Neoplasms 263 Precursor Cell Lymphoblastic Leukemia-Lymphoma 254 Endometrial Neoplasms 234 Lymphoma 228 Rectal Neoplasms 222 Esophageal Neoplasms 222 Sarcoma 213 Carcinoma, Renal Cell 203 Colonic Neoplasms 194 Lymphoma, Non-Hodgkin 191

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Interventional × Pan-tumor × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡